Summit Therapeutics (NasdaqGM:SMMT) FY Conference Transcript

Summit Therapeutics FY Conference Summary Company Overview - Company: Summit Therapeutics (NasdaqGM:SMMT) - Focus: Development of ivonesimab, a PD-1/VEGF bispecific antibody, in collaboration with Akeso Bio Key Points Partnership with Akeso - Summit entered a partnership with Akeso Bio in December 2022 for ivonesimab, which became effective in January 2023 [4] - Akeso was conducting two Phase III studies in non-small cell lung cancer (NSCLC) at the time of the partnership [4] - Summit expanded the HARMONi study into a global study and initiated additional studies in various cohorts [5][6] Clinical Development Pipeline - Multiple Phase III studies are ongoing, including: - HARMONi in post-TKI EGFR mutant lung cancer - HARMONi-3 in frontline non-small cell lung cancer - HARMONi-7 in PD-L1 high non-small cell lung cancer - A new study in microsatellite stable colorectal cancer [6][7] - The ILLUMINATE study will focus on frontline PD-L1 positive head and neck squamous cell carcinoma [7] Unique Aspects of Ivonesimab - Ivonesimab is positioned as a unique bispecific agent with advantages in binding and cooperativity compared to other PD-1/VEGF agents [9][10] - The design allows for intramolecular cooperativity, enhancing efficacy [9][10] FDA Interactions and Approval Process - The FDA accepted the Biologics License Application (BLA) for ivonesimab, with a PDUFA date set for November 2026 [12][13] - Ongoing discussions with the FDA have been productive, with a traditional review cycle expected [14] Clinical Data and Efficacy - Four Phase III studies have shown positive data, with HARMONi demonstrating statistically significant progression-free survival (PFS) benefits [17][19] - Overall survival (OS) data showed a nominal p-value of 0.03, indicating potential benefits despite initial non-significance [18][19] - The safety profile of ivonesimab is considered manageable compared to existing treatments [19][20] Market Opportunity - The total available market for ivonesimab is estimated to be larger than the current focus on EGFR mutant NSCLC, with potential in various PD-1 and VEGF sensitive tumors [26] - The company aims to build relationships with thoracic oncologists through early market entry [27] Future Studies and Expectations - An interim analysis for HARMONi-3 is planned for Q2 2026, with expectations for positive outcomes based on historical data [30][31] - The final PFS analysis for non-squamous cohorts is expected in the first half of 2027 [44] Colorectal Cancer Expansion - Enrollment has begun for a study in microsatellite stable colorectal cancer, with promising Phase II data supporting this direction [57][58] - The study aims to address a significant unmet need in colorectal cancer treatment [58] Head and Neck Cancer Study - A new study in head and neck cancer is being initiated in collaboration with the GORTEC cooperative group, expanding the scope of ivonesimab's application [69][70] Investor Insights - The unique design and competitive advantages of ivonesimab are considered underappreciated by investors [72][73] - The company emphasizes that not all PD-1/VEGF agents are interchangeable, highlighting the importance of ivonesimab's clinical track record [73] Conclusion Summit Therapeutics is advancing its clinical pipeline for ivonesimab through strategic partnerships and a focus on unique therapeutic advantages. The company is positioned to address significant unmet needs in oncology, with ongoing studies and a robust development strategy aimed at securing regulatory approvals and market presence.